Follow The Filings

RLMD Relmada Therapeutics

Relmada Therapeutics earnings company data as of 4:48 AM ET 10/23

Limited consensus data for this ticker (thin coverage or data-plan limits). Dates may be company-announced rather than sell-side consensus. Calendar and recent prints remain the primary lens when available.

Scheduled

1 period, newest first, nothing reported yet. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 12 Nov EPS — — —
Rev — — —

Insider trades

Open-market buys and sales by RLMD's executives, directors and 10% owners in the last 12 months, from their Form 4s

All RLMD insider trades
  • $4M bought by 4 insiders
  • None no sales outside a trading plan
  • None no planned (10b5-1) sales
  1. Maged Shenouda CFO
    Buy
    $844K 200,000 shares at $4.22 +25% to stake
    Traded Sep 9–10 Filed Sep 11
    ↗
  2. Sergio Traversa CEO
    Buy
    $828K 200,000 shares at $4.14 +15% to stake
    Traded Sep 9–10 Filed Sep 11
    ↗
  3. Sergio Traversa CEO
    Buy
    $113K 27,500 shares at $4.12 +2.2% to stake
    Traded Dec 15, 2025 Filed Dec 16, 2025
    ↗
  4. Maged Shenouda CFO
    Buy
    $48K 11,665 shares at $4.12 +1.5% to stake
    Traded Dec 15, 2025 Filed Dec 16, 2025
    ↗
  5. Chuck Ence COO
    Buy
    $299K 136,000 shares at $2.20 +51% to stake
    Traded Nov 5, 2025 Filed Nov 6, 2025
    ↗
  6. Sergio Traversa CEO
    Buy
    $600K 272,500 shares at $2.20 +27% to stake
    Traded Nov 5, 2025 Filed Nov 6, 2025
    ↗
  7. Maged Shenouda CFO
    Buy
    $1.1M 500,000 shares at $2.20 +173% to stake
    Traded Nov 5, 2025 Filed Nov 6, 2025
    ↗
  8. Paul Edward Kelly COO
    Buy
    $198K 90,000 shares at $2.20 +22% to stake
    Traded Nov 5, 2025 Filed Nov 6, 2025
    ↗

SEC filings

Recent issuer filings from EDGAR, 25 shown.

Filed Form Detail Links
8-K 8.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
10-Q QUARTERLY REPORT Filing Doc
8-K 2.02,7.01,9.01 Filing Doc
SCHEDULE 13G — Filing Doc
8-K 7.01,9.01 Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G — Filing Doc
8-K 5.03,5.07,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
10-Q QUARTERLY REPORT Filing Doc
8-K 2.02,7.01,9.01 Filing Doc
SCHEDULE 13G — Filing Doc
DEF 14A PROXY STATEMENT Filing Doc
DEFA14A DEFINITIVE ADDITIONAL MATERIALS Filing Doc
424B3 PROSPECTUS Filing Doc
8-K 2.02,7.01,9.01 Filing Doc
10-K ANNUAL REPORT Filing Doc
8-K 1.01,3.02,7.01,8.01,9.01 Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G — Filing Doc
424B5 PROSPECTUS SUPPLEMENT Filing Doc
8-K 5.02,9.01 Filing Doc

Source: SEC EDGAR submissions, updated 5 days ago. All on EDGAR

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.